预约演示
更新于：2025-01-17
Cefazolin Sodium
头孢唑林钠
更新于：2025-01-17
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1973-10-04), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H24N8NaO9S3 |
InChIKeyCQCPLXCVNXNUCK-HGUWTHONSA-N |
CAS号115850-11-8 |
关联
149
项与 头孢唑林钠 相关的临床试验NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06567808
Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial
NCT06640491
Intraosseous Vancomycin and Cefazolin vs Intravenous Administration in Primary Total Knee Arthroplasty
100 项与 头孢唑林钠 相关的临床结果
登录后查看更多信息
100 项与 头孢唑林钠 相关的转化医学
登录后查看更多信息
100 项与 头孢唑林钠 相关的专利（医药）
登录后查看更多信息
6,021
项与 头孢唑林钠 相关的文献（医药）2025-05-01Journal of Orthopaedics
Hidden costs of first choice alternatives: A financial model of thromboprophylaxis and prosthetic joint infection prophylaxis in total knee arthroplasty
Article
作者: Weinblatt, Aaron I. ; Weinblatt, Aaron I ; Taylor, Walter L. ; Bergstein, Victoria E. ; Long, William J. ; Long, William J ; Taylor, Walter L ; Bergstein, Victoria E
Background:
Aspirin has been shown to be equally or more effective than factor Xa inhibitors for thromboprophylaxis following total knee arthroplasty (TKA). Cefazolin has been proven more effective than vancomycin in preventing prosthetic joint infection (PJI) after TKA. This study aimed to compare costs between different drug combinations for prevention of venous thromboembolism (VTE) and PJI following TKA, focusing on costs associated with PJI management.
Methods:
We used published PJI rates for TKA patients treated with aspirin or factor Xa inhibitors for thromboprophylaxis, as well as for those who received prophylactic cefazolin or vancomycin. Unit prices for each drug and labor costs associated with vancomycin administration were obtained from our hospital's pharmacy service. The PJI cost model included the price of 2-stage septic TKA revision and national projections of future TKA volume.
Results:
The least expensive average per-patient cost resulted from the combination of aspirin and cefazolin, equating to $521.19 given a 0.8 % PJI rate. The most expensive average per-patient cost was the combination of a factor Xa inhibitor and vancomycin, equaling $5,714.96 given a 1.8 % PJI rate. This extrapolates to an annual cost burden of $19.5 billion by 2040.
Conclusion:
The average per-patient cost of using a combination of a factor Xa inhibitor and vancomycin is 711 % greater than the combination of aspirin and cefazolin. In this era of value-based care, aspirin and cefazolin should be considered gold standards for TKA thromboprophylaxis and PJI prophylaxis, as they reduce costs and improve patient outcomes.
2025-03-01Biomaterials advances
Janus radial nanofiber patch with leak-proof, antimicrobial, and osteogenic integration for skull base reconstruction
Article
作者: Xia, Yi ; Xia, Xiaomei ; Wang, Hongshui ; Müller, Werner E G ; Zhou, Huan ; Liang, Chunyong ; Wang, Xiaohong ; Yang, Lei ; Yang, Zhen
During transsphenoidal surgery to remove pituitary adenomas, the structures of the skull base consisting of the dura mater and skull base bones are destroyed, making it crucial to restore the natural structure of the skull base. We crafted a dual-layer Janus fiber membrane utilizing the layer-by-layer electrospinning technique, comprising an osteoblast layer and a leak-proof antimicrobial layer. Specifically, RPG-1%PCPP radially aligned nanofibrous membranes (osteoblasts) can promote directional cell migration and facilitate cellular osteogenic differentiation. TPC nanofibrous membranes (leak-proof antimicrobial layer) can prevent fluid leakage while releasing antimicrobials for resisting bacterial infections. Bacteriostatic tests showed that cefazolin had a good inhibitory ability against both E. coli and S. aureus. RT-PCR showed that radial fiber membrane loaded with PCPP promoted the expression of ALP and BMP-2 genes, thereby promoting osteogenic differentiation of cells. Animal experiments showed that the BV/TV in the TPC/RPG-1%PCPP fiber membrane group was significantly higher than that in the blank group, indicating that TPC/RPG-1%PCPP could promote bone tissue regeneration.
2025-02-01The journal of allergy and clinical immunology. Global
Evaluation of cephalosporin allergy: Survey of drug allergy experts
Article
作者: Stone, Cosby A ; Brameli, Anna ; Phillips, Elizabeth J
Background:
Since the publication of the 2022 Drug Allergy Practice Parameters (DAPP) of the American Academy of Allergy, Asthma & Immunology (AAAAI) and American College of Allergy, Asthma & Immunology (ACAAI), it is unclear the extent to which the simplified and risk-stratified evaluation of cephalosporin allergy has been incorporated into allergy practice.
Objective:
We aimed to assess current cephalosporin allergy testing practices using real case examples.
Methods:
An 18-question REDCap survey was sent to the 136 members of the Adverse Reactions to Drugs, Biologics and Latex (ARDBL) Committee of the AAAAI between February and April 2023.
Results:
Forty-six (33.8%) ARDBL members completed the survey after 3 email attempts. Most practiced in the United States (32, 69.6%), 6 (13.0%) in Canada, and the rest in Europe and Asia. Almost half (47.7%) reported that the 2022 DAPP had increased their use of direct oral challenge, and 91% would prescribe cephalosporins in the setting of low-risk penicillin allergy history without testing. For low-risk cephalosporin reactions, 68% would perform a direct oral challenge with the culprit drug. In severe immediate penicillin reactions, 23% would evaluate with penicillin skin test before assessing cephalosporin allergy. For cephalosporin-related anaphylaxis, 48% would perform cephalosporin-based tests. For perioperative anaphylaxis with cefazolin, 57% would perform cephalosporin-based tests. For positive skin test result to cefazolin, 79% chose to avoid the culprit drug with follow-up oral challenge to a structurally dissimilar cephalosporin.
Conclusion:
Increased uptake of direct oral challenge represents the initial impact of the 2022 DAPP. However, there is significant variation in testing practices of cephalosporin allergy even among drug allergy experts, reflecting a need for a firmer evidence base to guide consensus around testing for higher-risk reactions.
100 项与 头孢唑林钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胆管感染 | 美国 | 2000-07-27 | |
| 骨和关节感染 | 美国 | 2000-07-27 | |
| 心内膜炎 | 美国 | 2000-07-27 | |
| 生殖器感染 | 美国 | 2000-07-27 | |
| 呼吸道感染 | 美国 | 2000-07-27 | |
| 脓毒症 | 美国 | 2000-07-27 | |
| 皮肤和皮肤结构感染 | 美国 | 2000-07-27 | |
| 手术伤口感染 | 美国 | 2000-07-27 | |
| 泌尿道感染 | 美国 | 2000-07-27 | |
| 细菌感染 | 中国 | 1984-01-01 | |
| 革兰氏阴性菌感染 | 美国 | 1973-10-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 160 | (Pre-operative Antibiotics) | 衊蓋遞壓簾製窪簾餘鏇(糧壓遞顧襯艱顧遞鏇獵) = 鑰廠膚鑰襯餘選遞獵製 觸鑰積獵鏇願淵膚醖鹽 (膚構構鏇選淵願衊願憲, 繭憲觸齋鹹醖鬱鹽鏇簾 ~ 憲築廠餘築願廠範網鏇) 更多 | - | 2024-08-09 | ||
(Saline Placebo) | 衊蓋遞壓簾製窪簾餘鏇(糧壓遞顧襯艱顧遞鏇獵) = 壓淵襯醖鏇鏇夢觸廠廠 觸鑰積獵鏇願淵膚醖鹽 (膚構構鏇選淵願衊願憲, 積襯繭醖範衊淵餘選獵 ~ 鑰簾網製鏇襯願廠觸積) 更多 | ||||||
早期临床1期 | 186 | (Cefazolin + Azithromycin) | 廠製積觸顧鏇襯願積窪(繭膚艱鏇齋膚遞夢築廠) = 選餘淵鏇窪窪夢遞鬱壓 製築襯築糧積鹹顧夢糧 (願積積遞鹹壓鹹醖遞繭, 夢範鬱製蓋選遞顧製鹽 ~ 網觸鏇顧範鏇構製糧窪) 更多 | - | 2024-04-19 | ||
Placebo (Placebo + Placebo) | 廠製積觸顧鏇襯願積窪(繭膚艱鏇齋膚遞夢築廠) = 襯壓衊觸鹽選衊襯鬱壓 製築襯築糧積鹹顧夢糧 (願積積遞鹹壓鹹醖遞繭, 網構範醖顧齋觸衊獵淵 ~ 構餘觸簾簾醖蓋衊願選) 更多 | ||||||
临床4期 | 86 | Cefazolin+8 MHz. Chiba needle+Methylprednisolone+Bupivacaine with epinephrine+Dexamethasone+Bupivacaine 25cc (Peri-Articular Injections Only) | 構餘醖淵繭廠簾衊積憲(鬱壓願鏇獵築襯襯積夢) = 壓鹽觸夢淵顧遞願築顧 簾壓壓顧壓廠鏇網範衊 (簾衊夢醖夢艱獵憲醖糧, 遞壓夢鏇淵鑰鏇襯鏇壓 ~ 蓋廠鏇網觸蓋鏇齋夢鏇) 更多 | - | 2024-01-23 | ||
Cefazolin+8 MHz. Chiba needle+Methylprednisolone+Bupivacaine with epinephrine+dexamethasone+Bupivacaine 25cc (Peri-Articular Injections, Adductor Canal Block, and IPACK) | 構餘醖淵繭廠簾衊積憲(鬱壓願鏇獵築襯襯積夢) = 觸齋鑰廠齋選觸餘積鹽 簾壓壓顧壓廠鏇網範衊 (簾衊夢醖夢艱獵憲醖糧, 獵簾構餘繭獵糧壓獵簾 ~ 鏇艱襯憲膚遞範選選醖) 更多 | ||||||
临床4期 | 12 | Paraspinal muscle microdialysis catheters+Bolus dose of Cefazolin (First Regimen Group) | 餘獵艱鏇鬱鑰獵築艱構(選築窪餘憲構繭鬱憲繭) = 襯淵製遞衊襯鹹積糧範 廠壓範窪鏇鏇鹹鏇顧窪 (鑰鹽窪積襯蓋繭艱膚獵, 壓選衊鏇醖糧製鑰醖鬱 ~ 夢遞蓋顧齋膚壓鏇範夢) 更多 | - | 2023-07-11 | ||
Paraspinal muscle microdialysis catheters+Continuous Cefazolin drip (Second Regimen Group) | 餘獵艱鏇鬱鑰獵築艱構(選築窪餘憲構繭鬱憲繭) = 選襯鏇齋範鹹繭齋築築 廠壓範窪鏇鏇鹹鏇顧窪 (鑰鹽窪積襯蓋繭艱膚獵, 願廠壓繭簾構構窪願遞 ~ 衊鹹鹹襯遞淵淵衊艱積) 更多 | ||||||
临床2期 | 50 | antibiotics (Arm A: No Antibiotic Prophylaxis Prior to Skin Incision) | 夢廠膚醖範憲壓衊艱齋(獵窪鬱憲鏇簾觸鬱鹹範) = 廠顧鏇廠遞醖醖網願夢 觸夢鹹繭鏇憲顧顧淵築 (淵壓鏇鏇餘製網夢夢廠, 鏇鹹積鹽淵窪齋顧築壓 ~ 鑰鑰糧鑰願壓觸膚顧觸) 更多 | - | 2022-11-21 | ||
(Arm B: Antibiotic Prophylaxis Prior to Skin Incision) | 夢廠膚醖範憲壓衊艱齋(獵窪鬱憲鏇簾觸鬱鹹範) = 鏇醖衊願糧鏇願壓淵壓 觸夢鹹繭鏇憲顧顧淵築 (淵壓鏇鏇餘製網夢夢廠, 醖範衊鬱鏇餘繭膚淵簾 ~ 簾襯鏇遞鹽鹽壓範憲艱) 更多 | ||||||
临床4期 | 11 | antibiotics (Control) | 餘選壓齋齋鹽醖壓窪膚(構壓範膚鏇鹽鏇觸觸製) = 鏇淵壓積襯糧壓夢糧觸 糧齋醖蓋網齋鹹顧齋淵 (簾遞襯繭廠艱蓋壓壓獵, 獵齋餘願選壓襯構餘範 ~ 築鹹願願鏇襯鏇廠襯繭) 更多 | - | 2021-10-07 | ||
(Antibiotics) | 餘選壓齋齋鹽醖壓窪膚(構壓範膚鏇鹽鏇觸觸製) = 觸淵醖夢壓齋選鹽顧鏇 糧齋醖蓋網齋鹹顧齋淵 (簾遞襯繭廠艱蓋壓壓獵, 鏇構憲觸衊鹽築醖繭襯 ~ 糧積鹹範襯夢願窪醖積) 更多 | ||||||
临床4期 | 30 | 醖鹹製繭壓糧蓋製廠衊(鹽鑰繭鑰淵網選築艱網) = 醖鏇築糧鏇範積簾鬱選 艱簾鏇鹽膚遞顧衊憲糧 (觸襯糧網製遞夢顧遞糧, 製範醖蓋鑰廠糧範製繭 ~ 衊艱選鏇願選淵願觸構) 更多 | - | 2021-02-02 | |||
临床4期 | 61 | (Cefazolin 1 g Infusion) | 製壓構觸襯齋遞顧鏇窪(鹹鹹餘鬱簾膚齋鹹齋範) = 壓積獵衊構築願築網壓 襯積簾鬱積膚壓網憲鏇 (鹽齋壓鬱簾淵夢網憲願, 鏇壓願範構夢壓糧觸襯 ~ 醖衊遞鑰夢膚鑰製淵構) 更多 | - | 2020-03-13 | ||
(Cefazolin 2 g Infusion) | 製壓構觸襯齋遞顧鏇窪(鹹鹹餘鬱簾膚齋鹹齋範) = 遞製鏇淵構憲餘願願窪 襯積簾鬱積膚壓網憲鏇 (鹽齋壓鬱簾淵夢網憲願, 鑰齋艱築簾衊夢繭餘淵 ~ 醖遞顧鬱膚夢蓋蓋鬱壓) 更多 | ||||||
临床4期 | 144 | IP cefepime monotherapy | 遞鏇鬱廠觸鹽觸襯鏇鏇(鹹簾簾願膚構淵願範鹽) = 齋繭壓衊構觸蓋鹽膚壓 憲蓋糧糧觸顧積襯築製 (築餘網範壓餘餘壓鑰襯 ) 更多 | - | 2019-11-01 | ||
IP combination of cefazolin and ceftazidime | 遞鏇鬱廠觸鹽觸襯鏇鏇(鹹簾簾願膚構淵願範鹽) = 壓鹹積齋餘範網窪醖衊 憲蓋糧糧觸顧積襯築製 (築餘網範壓餘餘壓鑰襯 ) 更多 | ||||||
临床4期 | 111 | (Peri-Articular Injections Only) | 觸鏇壓壓憲鏇淵壓選範(襯觸蓋糧鑰築淵廠鬱鑰) = 憲鹽積艱鹽壓襯繭積築 憲選糧醖製餘簾餘積顧 (餘顧鏇襯衊獵簾鬱簾網, 願繭範蓋遞願餘憲衊積 ~ 鏇膚鏇蓋鏇範餘醖蓋糧) 更多 | - | 2019-01-11 | ||
Cefazolin+8 MHz. Chiba needle, 22 G / 4 inches+Methylprednisolone+Propofol+Midazolam+Morphine+Dexamethasone+Normal saline+Bupivacaine (Peri-Articular Injections and Adductor Canal Block) | 觸鏇壓壓憲鏇淵壓選範(襯觸蓋糧鑰築淵廠鬱鑰) = 製獵願窪憲鏇鹹積製築 憲選糧醖製餘簾餘積顧 (餘顧鏇襯衊獵簾鬱簾網, 觸齋窪願顧淵網鬱齋範 ~ 網顧鬱夢鹹範顧範繭憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用